Patient-reported outcomes as end points and outcome indicators in solid tumours

Nature Reviews Clinical Oncology

Volumn 12, Issue 6, 2015, Pages 358-370

  Secord, Angeles A ^a   Coleman, Robert L ^b,d,e   Havrilesky, Laura J ^a   Abernethy, Amy P ^b   Samsa, Gregory P ^c   Cella, David ^f  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Division of Medical Oncology   (United States)

^c Department of Biostatistics and Bioinformatics ^*  (United States)

^d DUKE CANCER INSTITUTE   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATRASENTAN; CAPECITABINE; CISPLATIN; DOCETAXEL; DOXORUBICIN; EXATECAN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; LEVOLEUCOVORIN; NAVELBINE; OXALIPLATIN; PACLITAXEL; PLACEBO; RISEDRONIC ACID; RUBITECAN; SUNITINIB; TEMOZOLOMIDE; VINFLUNINE;

BILIARY TRACT CANCER; BLADDER CANCER; BRAIN CANCER; BREAST CANCER; CANCER PROGNOSIS; CANCER SURVIVAL; CHEMORADIOTHERAPY; COLORECTAL CANCER; ESOPHAGUS CANCER; GLIOBLASTOMA; HEALTH CARE QUALITY; HUMAN; KIDNEY CARCINOMA; LIVER CANCER; LUNG CANCER; MELANOMA; MOUTH CANCER; NASOPHARYNX CANCER; NON SMALL CELL LUNG CANCER; OVARY CANCER; PANCREAS CANCER; PATIENT REPORTED OUTCOME; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOLID TUMOR; STOMACH CANCER; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME; TREATMENT RESPONSE; UTERINE CERVIX CANCER; CLINICAL TRIAL (TOPIC); FORECASTING; MORTALITY; NEOPLASMS; OUTCOME ASSESSMENT; PATIENT CARE; SELF REPORT; SURVIVAL ANALYSIS;

CLINICAL TRIALS AS TOPIC; FORECASTING; HUMANS; NEOPLASMS; PATIENT OUTCOME ASSESSMENT; PATIENT-CENTERED CARE; QUALITY OF LIFE; SELF REPORT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84930178766     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2015.29     Document Type: Review

References (88)

1. Wildiers, H. et al. End p oints and trial design in geriatric oncology research: a joint European Organisation for Research and Treatment of Cancer-Alliance for Clinical Trials in Oncology-International Society Of Geriatric Oncology position article. J. Clin. Oncol. 31, 3711-3718 (2013).
2. Patient-reported outcomes in performance measurement. National Quality Forum [online] http://www.qualityforum.org/Publications/2012/12/Patient-Reported-Outcomes-in-Performance-Measurement.aspx (2012).
3. Coons, S. J. & Kaplan, R. M. Assessing health-related quality of life: application to drug therapy. Clin. Ther. 14, 850-858 (1992).
4. Bottomley, A., Vanvoorden, V., Flechtner, H. & Therasse, P. The challenges and achievements involved in implementing quality of life research in cancer clinical trials. Eur. J. Cancer 39, 275-285 (2003).
5. Cella, D. F. et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J. Clin. Oncol. 11, 570-579 (1993).
6. Aaronson, N. K. et al. The European Organisation for Rese arch and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J. Natl Cancer Inst. 85, 365-376 (1993).
7. Wagner, L. I., Wenzel, L., Shaw, E. & Cella, D. Patient-reported outcomes in phase II cancer clinical trials: lessons learned and future directions. J. Clin. Oncol. 25, 5058-5062 (2007).
8. Trotti, A. et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin. Radiat. Oncol. 13, 176-181 (2003).
9. Gotay, C. C., Kawamoto, C. T., Bottomley, A. & Efficace, F. The prognostic significance of patient-reported outcomes in cancer clinical trials. J. Clin. Oncol. 26, 1355-1363 (2008).
10. Quinten, C. et al. Baseline quality of life as a prognostic indicator of survival: a meta-Analys is of individual patient data from EORTC clinical trials. Lancet Oncol. 10, 865-871 (2009).
11. Meropol, N. J. et al. Cancer patient preferences for quality and length of life. Cancer 113, 3459-3466 (2008).
12. Victorson, D., Soni, M. & Cella, D. Metaanalysis of the correlation between radiographic tumor response and patient-reported outcomes. Cancer 106, 494-504 (2006).
13. Kris, M. G. et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290, 2149-21 58 (2003).
14. Reckamp, K. L. et al. A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal grow th factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib. Cancer 120, 1145-1154 (2014).
15. Jones, D. et al. The validi ty and utility of the MD Anderson Symptom Inventory in patients with prostate cancer: evidence from the Symptom Outcomes and Practice Patterns (SOAPP) data from the Eastern Cooperative Oncology Group. Clin. Genitourin. Cancer 12, 41-49 (2014).
16. Osoba, D. Health-related quality of life and cancer clinical trials. Ther. Adv. Med. Oncol. 3, 57-71 (2011).
17. Schmidt, M. et al. Prediction of long-term mortality by preoperative health-related quality-of-life in elderly onco-surgical patients. PLoS ONE 9, e85456 (2014).
18. Sehlen, S. et al. Health-related quality of life supersedes other psychosocial predictors of long-term survival in cancer patients undergoing radiotherapy. Acta Oncol. 51, 1020-1028 (2012).
19. Eton, D. T. et al. Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: results from Eastern Cooperative Oncology Group Study 5592. J. Clin. Oncol. 21, 1536-1543 (2003).
20. Chase, D. M. et al. Quality of life and survival in advanced cervical cancer: a Gynecologic Oncology Group study. Gynecol. Oncol. 125, 315-319 (2012).
21. Carey, M. S. et al. The prognostic effects of performance status and quality of life scores on progression-free survival and overall survival in advanced ovarian cancer. Gynecol. Oncol. 108, 100-105 (2008 ).
22. Oken, M. M. et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. 5, 649-655 (1982).
23. Ko, A. H. & Cella, D. Achievi ng the best of both worlds. J. Clin. Oncol. 31, 3-4 (2013).
24. Lilenbaum, R. C., Cashy, J., Hensing, T. A., Young, S. & Cella, D. Prevalence of poor performance status in lung cancer p atients: implications for research. J. Thorac. Oncol. 3, 125-129 (2008).
25. Quinten, C. et al. Patient self-reports of symptoms and clinician ratings as predictors of overall cancer survival. J. Natl Cancer Inst. 103, 1851-1858 (2011).
26. Burris, H. A. 3rd et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomize d trial. J. Clin. Oncol. 15, 2403-2413 (1997).
27. Amir, E., Seruga, B., Kwong, R., Tannock, I. F. & Ocana, A. Poor correlation between progression-free and overall survival in modern clinical trials: are composite endpoints the answer Eur. J. Cancer 48, 385-388 (2012).
28. Ohorodnyk, P., Eisenhauer, E. A. & Booth, C. M. Clinical benefit in oncology trials: is this a patient-centred or tumour-centred end-point? Eur. J. Cancer 45, 2249-2252 (2009).
29. Bellmunt, J. et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J. Clin. Oncol. 27, 4454-4461 (2009).
30. Rothenberg, M. L. et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinote can and fluorouracil-leucovorin: interim results of a phase III trial. J. Clin. Oncol. 21, 2059-2069 (2003).
31. Fields-Jones, S. et al. Improvements in clinical benefit with vinorelbine in the treatment of hormone-refractory prostate cancer: a phase II trial. Ann. Oncol. 10, 1307-1310 (1999).
32. Louvet, C. et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J. Clin. Oncol. 23, 3509-3516 (2005).
33. Colucci, G. et al. Randomized phase III trial of gemcitabine plus cisplatin compared wit h single-Agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J. Clin. Oncol. 28, 1645-1651 (2010).
34. Bernhard, J. et al. Clinical benefit and quali ty of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial-SAKK 44/00-CECOG/PAN.1.3.001. J. Clin. Oncol. 26, 3695-3701 (2008).
35. Abou-Alfa, G. K. et al. Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J. Clin. Oncol. 24, 4441-4447 (2006).
36. Cherny, N. I. et al. Improving the methodologic and ethical validity of best supportive care studies in oncology: lessons from a systematic review. J. Clin. Oncol. 27, 5476-5486 (2009).
37. Currow , D. C., Foley, K., Zafar, S. Y., Wheeler, J. L. & Abernethy, A. P. The need for a re-evaluation of best supportive care studies reported to date. Br. J. Cancer 104, 390-391 (2011).
38. Zafar, S. Y., Currow, D. & Abernethy, A. P. Defining best supportive care. J. Clin. Oncol. 26, 5139-5140 (2008).
39. Zafar, S. Y. et al. Consensus-based standards for best supportive care in clinical trials in advanced cancer. Lancet Oncol. 13, e77-e82 (2012).
40. Conroy, T. et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 364, 1817-1825 (2011).
41. Gourgou-Bourgade, S. et al. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. J. Clin. Oncol. 31, 23-29 (2013).
42. Armstrong, T. S. et al. Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed gl ioblastoma. J. Clin. Oncol. 31, 4076-4084 (2013).
43. Gilbert, M. R. et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J. Clin. Oncol. 31, 4085-4091 (2013).
44. Keller, A. M. et al. Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cance r. J. Clin. Oncol. 22, 3893-3901 (2004).
45. Seymour M. T.,et al. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial Lancet 377 1749-1759 2011).
46. Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228-247 (2009).
47. Cleeland, C. S. et al. Recommendations for including multiple symptoms as endpoints in cancer clinical trials: a report from the ASCPRO (Assessing the Symptoms of Cancer Using Patient-Reported Outcomes) Multis ymptom Task Force. Cancer 119, 411-420 (2013).
48. Reeve, B. B. et al. ISOQOL recommends minimum standards for patient-reported outcome measures used in patient-centered outcomes and comparative effectiveness research. Qual. Life Res. 22, 1889-1905 (2013).
49. Havrilesky, L. J. et al. Relative influence of factors determining a woman's preference for treatment options in ovarian cancer: a prospective study [abstract]. J. Clin. Oncol. 32 (5s Suppl.), a5544 (2014).
50. Ryan, M. & Farrar, S. Using conjoint analysis to elicit preferences for health care. BMJ 320, 1530-1533 (2000).
51. Bridges, J. F., Mohamed, A. F., Finnern, H. W., Woehl, A. & Ha uber, A. B. Patients' preferences for treatment outcomes for advanced non-small cell lung cancer: a conjoint analysis. Lung Cancer 77, 224-231 (2012).
52. Roychowdhury, D. F., Hayden, A. & Liepa, A. M. Health-related quality-of-life parameters as independent prognostic factors in advanced or metastatic bladder cancer. J. Clin. Oncol. 21, 673-678 (2003).
53. Brown, P. D. et al. Prospective study of quality of life in adults with newly diagnosed high-grade gliomas. J. Neurooncol. 76, 283-291 (2006).
54. Tross, S. et al. Psychological symptoms and disease-free and over-All survival in women with stage II breast cancer: Cancer and Leukemia Group B. J. Natl Cancer Inst. 88, 661-667 (1996).
55. Coates, A. S. et al. Quality-of-life scores predict outcome in metastatic but not early breast cancer: International Breast Cancer Study Group. J. Clin. Oncol. 18, 3768-3774 (2000).
56. Efficace, F. et al. Health-related quality of life parameters as prognostic factors in a nonmetastatic breast cancer population: An international multicenter study. J. Clin. Oncol. 22, 3381-3388 (2004).
57. Coates, A. et al. Prognostic value of quality-of-life scores during chemo-therapy for advanced breast cancer: Australian New Zealand Breast Cancer Trials Group. J. Clin. Oncol. 10, 1833-1838 (1992).
58. Monk, B. J. et al. Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group Study. J. Clin. Oncol. 23, 4617-4625 ( 2005).
59. Maisey, N. R. et al. Baseline quality of life predicts survival in patients with advanced colorectal cancer. Eur. J. Cancer 38, 1351-1357 (2002).
60. Efficace, F. et al. Does a patient's self-reported health-related quality of life predict survival beyond key biomedical data in advanced colorectal cancer Eur. J. Cancer 42, 42-49 (2006).
61. Chau, I. et al. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer: pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J. Clin. Oncol. 22, 2395-2403 (2004).
62. Park, S. H. et al. Self-reported health-related quality of life predicts survival for patients with advanced gastric cancer treated with first-line chemotherapy. Qual. Life Res. 17, 207-214 (2008).
63. Yeo, W. et al. Quality of life is predictive of survival in patients with unresectable hepatocellular carcinoma. Ann. Oncol. 17, 1083-1089 (2006).
64. Kaasa, S., Mastekaasa, A. & Lund, E. Prognostic factors for patients with inoperable non-small cell lung cancer, limited disease: the importance of patients' subjective experience of disease and psychosocial well-being. Radiother. Oncol. 15, 235-242 (1989).
65. Ruckdeschel, J. C. & Piantadosi, S. Quality of life in lung cancer surgical adjuvant trials. Chest 106, 324S-328S (1994).
66. Langendijk H.,et al The prognostic impact of qua lity of life assessed with the EORTC QLQ-C30 in inoperable non-small cell lung carcinoma treated with radiotherapy. Radiother. Oncol. 55, 19-25, 2000).
67. Naughton, M. J. et al. The health-related quality of life and survival of small-cell lung cancer patients: results of a companion study to CALGB 9033. Qual. Life Res. 11, 235-248 (2002).
68. Loprinzi, C. L. et al. Prospective evaluation of prognostic variables from patient-completed questionnaires: North Central Cancer Treatment Group. J. Clin. Oncol. 12, 601-607 (1994).
69. Coates, A. et al. Prognostic value of quality of life scores in a trial of chemotherapy wi th or without interferon in patients with metastatic malignant melanoma. Eur. J. Cancer 12, 1731-1734 (1993).
70. Chiarion-Sileni, V. et al. Quality of life evaluation in a randomised trial of chemotherapy versus bio-chemotherapy in advanced melanoma patients. Eur. J. Cancer 39, 1577-1585 (2003).
71. Fang, F. M. et al. Pretreatment quality of life as a predictor of distant metastasis and survival for patients with nasopharyngeal carcinoma. J. Clin. Oncol. 28, 4384-4389 (2010).
72. Tarsitano, A ., Pizzigallo, A., Ballone, E. & Marchetti, C. Health-related quality of life as a survival predictor for patients with oral cancer: is quality of life associated with long-term overall survival? Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 114, 756-763 (2012).
73. Fossa, S. D. et al. Prostate-specific antigen and other prognostic factors in patients with hormone-resistant prostatic cancer undergoing experimental treatment. Br. J. Urol. 69, 175-179 (1992).
74. Tannock, I. F. et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with pall iative end points. J. Clin. Oncol. 14, 1756-1764 (1996).
75. Collette, L. et al. Is baseline quality of life useful for predicting survival with hormone-refractory prostate cancer A pooled analysis of three studies of the European Organisation for Research and Treatment of Cancer Genitourinary Group. J. Clin. Oncol. 22, 3877-3885 (2004).
76. Sullivan, P. W., Nelson, J. B., Mulani, P. M. & Sleep, D. Q uality of life as a potential predictor for morbidity and mortality in patients with metastatic hormone-refractory prostate cancer. Qual. Life Res. 15, 1297-1306 (2006).
77. Cella, D. et al. Baseline quality of life as a prognostic survival tool in patients receiving sunitinib for metastatic renal cell carcinoma. Br. J. Cancer 106, 646-650 (2012).
78. Hidalgo, M. et al. Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. J. Clin. Oncol. 17, 585-592 (1999).
79. Lorusso, V. et al. Phase I/II study of gemcitabine plus vinorelbine as first-line chemotherapy of non-small-cell lung cancer. J. Clin. Oncol. 18, 405-411 (2000).
80. Matano, E. et al. Gemcitabine combined with continuous infusion 5-fluorouracil in advanced and symptomatic pancreatic cancer: a cli nical benefit-oriented phase II study. Br. J. Cancer 82, 1772-1775 (2000).
81. Cartwright, T. H. et al. Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J. Clin. Oncol. 20, 160-164 (2002).
82. Burris, H. A. 3rd et al. Phase II trial of oral rubitecan in previously treated pancreatic cancer patients. Oncologist 10, 183-190 (2005).
83. Huguet, F. et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J. Clin. Oncol. 25, 326-331 (2007).
84. Koeberle, D. et al. Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research. J. Clin. Onco l. 26, 3702-3708 (2008).
85. Krzakowski, M. et al. Phase III trial comparing vinflunine with docetaxel in second-line advanced non-small-cell lung cancer previously treated with platinum-containing chemothera py. J. Clin. Oncol. 28, 2167-2173 (2010).
86. Imamoto, H. et al. Assessing clinical benefit response in the treatment of gastric malignant ascites with non-measurable lesions: a multicenter phase II tr ial of paclitaxel for malignant ascites secondary to advanced/recurrent gastric cancer. Gastric Cancer 14, 81-90 (2011).
87. Meulenbeld, H. J. et al. Randomised phase II/III study of docetaxel wit h or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro). Eur. J. Cancer 48, 2993-3000 (2012).
88. Motzer, R. J. et al. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J. Clin. Oncol. 30, 1371-1377 (2012).